Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection

Kang HUANG; Zhirong ZHAO; Haiwen LI; Ti WU; Ting JIA; Lu WANG; Nihong LU; Yongrui YANG

doi:10.12259/j.issn.2095-610X.S20231119

Volume 44 Issue 11

Nov. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(11): 126-134

Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection[J]. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119

Citation:

Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection[J]. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119

Citation:

Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection[J]. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119

PDF( 1326 KB)

Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection

doi: 10.12259/j.issn.2095-610X.S20231119

Dept. of Hepatology，The 3rd Hospital of Kunming/Yunnan Provincial Center for Infectious Diseases Clinical Medicine，Kunming Yunnan 650041，China

Received Date: 2023-06-20
Available Online: 2023-11-04
Publish Date: 2023-11-30

Abstract

Abstract

Objective To investigate the efficacy and safety of Sofosbuvir/Velpatasvir ± ribavirin（SOF/VEL±RBV） in the treatment of genotype 3 chronic hepatitis C cirrhotic patients. Methods Patients diagnosed with genotype 3（GT3） HCV infection and treated at the Third People's Hospital of Kunming City from June 2018 to February 2023 were retrospectively included. All patients had liver cirrhosis and were treated with SOF/VEL＋RBV for 12 weeks, SOF/VEL therapy for 12 or 24 weeks if favorable ribavirin contrainminated or ribavirin intolerant. The virologic indexes, liver and kidney function indexes and adverse reactions of the patients were analyzed before treatment, 4 weeks, 12 weeks and 12 weeks after drug withdrawal. Results A total of 319 patients were included, including 308 cases in SOF/VEL+RBV group and 11 cases in SOF/VEL group. After 12 weeks off-treatment, the sustained virological response（SVR12） rate in SOF/VEL+ RBV group was 98.37%（303/308）, and the levels of APRI score and FIB-4 index were decreased compared with baseline（P < 0.05）. The levels of total bilirubin, aspartate aminotransferase and alanine aminotransferase were all decreased, and the differences were statistically significant（all P < 0.05）. The SVR12 rate of SOF/VEL group was 72.73%（8/11）. The adverse reactions were mild hemolytic anemia（15.26%）, fatigue（8.12%） and rash（8.77%） in SOF/VEL+RBV group, and fatigue（9.09%） in 1 case in SOF/VEL group. Conclusion SOF/VEL+RBV could achieve higher SVR12 and well tolerated for GT3 HCV-infected patients either with compensated cirrhosis or decompensated cirrhosis patients. Liver function, renal function and liver fibrosis could also be improved after treatment.
- Sofosbuvir/Velpatasvir,
- Chronic hepatitis C,
- Genotype 3,
- Liver cirrhosis,
- Virological response

FullText(HTML)

References(19)

References

[1]	Gao Y,Yang J,Sun F,et al. Prevalence of Anti-HCV antibody among the general population in Mainland China between 1991 and 2015: A systematic review and meta-analysis[J]. Open Forum Infect Dis,2019,6(3):1-7.
[2]	Mei X, Lu H. Prevalence, diagnosis, and treatment of hepatitis C in Mainland China[J/OL]. Glob Health Med, 2021, 3（5）: 270-275.
[3]	Qin Q,Smith M K,Wang L,et al. Hepatitis C virus infection in China: An emerging public health issue[J]. J Viral Hepat,2015,22(3):238-244. doi: 10.1111/jvh.12295
[4]	Yuanyuan J,Xiu Z,Wei Y,et al. The distribution of hepatitis C viral genotypes shifted among chronic hepatitis C patients in Yunnan,China,between 2008–2018[J]. Frontiers in Cellular and Infection Microbiology,2023,11(7):92-93.
[5]	Tayyab G U N,Rasool S,Nasir B,et al. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens[J]. BMC Gastroenterol,2020,20(1):93. doi: 10.1186/s12876-020-01249-4
[6]	陈红松,窦晓光,段钟平,等. 丙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015,31(12):1961-1979. doi: 10.3969/j.issn.1001-5256.2015.12.003
[7]	中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华传染病杂志,2023,41(1):29-46. doi: 10.3760/cma.j.cn311365-20230217-00045
[8]	Xia X,Luo J,Bai J,et al. Epidemiology of hepatitis C virus infection among injection drug users in China: Systematic review and meta-analysis[J]. Public Health,2008,122(10):990-1003. doi: 10.1016/j.puhe.2008.01.014
[9]	Lauer G M,Walker B D. Hepatitis C virus infection[J]. N Engl J Med,2001,345(1):41-52. doi: 10.1056/NEJM200107053450107
[10]	关富,王胜炳,张鸣青. 《2022年美国肝病学会实践指南:肝硬化失代偿期的症状管理和姑息性治疗》摘译[J]. 临床肝胆病杂志,2022,38(4):784-787.
[11]	叶晓婷,徐霜,张盛果,等. 索磷布韦/维帕他韦治疗基因3型和6型慢性丙型肝炎患者的疗效和安全性[J]. 温州医科大学学报,2023,53(8):662-666. doi: 10.3969/j.issn.2095-9400.2023.08.009
[12]	中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志,2019,27(12):962-979. doi: 10.3760/cma.j.issn.1007-3418.2019.12.008
[13]	Fabrizi F,Cerutti R,Dixit V,et al. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis[J]. Nefrologia (Engl Ed),2021,41(5):578-589.
[14]	江啸,姜晓娟,苏锐良,等. 基于索非布韦的方案联合利巴韦林治疗肝移植后HCV基因1型肝炎受者的Meta分析[J]. 器官移植,2019,10(5):570-577. doi: 10.3969/j.issn.1674-7445.2019.05.017
[15]	冯巩,宋娟娟,叶峰,等. 肝硬化再代偿:现状与挑战[J]. 临床肝胆病杂志,2023,39(10):2464-2469.
[16]	白金锡,白贞子,郑艳. 36例慢性丙型肝炎抗病毒副作用及对策[J]. 中国实验诊断学,2013,17(2):346-347.
[17]	赵智蓉,李海雯,李晓非,等. 索磷布韦维帕他韦联合利巴韦林治疗基因3型慢性丙肝患者的疗效与安全性[J]. 昆明医科大学学报,2021,42(3):98-103.
[18]	魏来, 谢青, 黄燕, 等. 索磷布韦/维帕他韦用于基因1-6型HCV中国患者时的安全性和疗效: 来自一项3期临床试验的结果[C]. 第十届全国疑难及重症肝病大会, 苏州, 2019.
[19]	Esteban R,Pineda J A,Calleja J L,et al. Efficacy of sofosbuvir and velpatasvir,with and without ribavirin,in patients with hepatitis C virus genotype 3 infection and cirrhosis[J]. Gastroenterology,2018,155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042

Relative Articles(20)

Relative Articles

[1]	Lu ZHANG, Ye LI, Qingqing WANG, Shenghao LI. Advances in Research on the Effects of Liver Cirrhosis on Cardiovascular System and Related Mechanisms. Journal of Kunming Medical University, 2024, 45(6): 1-6. doi: 10.12259/j.issn.2095-610X.S20240601
[2]	Peizheng XIANG, Mengli LI, Yan FU. Value of Multiple Scoring Systems in Evaluating the Prognosis of Liver Cirrhosis Complicated with Esophageal and Gastric Varices Bleeding. Journal of Kunming Medical University, 2022, 43(3): 128-134. doi: 10.12259/j.issn.2095-610X.S20220316
[3]	Siqi LI, Wenlin TAI. Significance of CXCL10 as a Biomarker of Liver Cirrhosis. Journal of Kunming Medical University, 2022, 43(7): 55-61. doi: 10.12259/j.issn.2095-610X.S20220711
[4]	Qingqing WANG, Jie DING, Hongjie YANG, Guoji CHANG, Siqi LIU, Lijuan HUA, Yiying WANG, Shenghao LI. Predictive Value of RDW and Blood Lipid on Gastroesophageal Variceal Bleeding in Patients with Liver Cirrhosis. Journal of Kunming Medical University, 2022, 43(5): 144-148. doi: 10.12259/j.issn.2095-610X.S20220509
[5]	Min ZHOU, Zhihui MA, Jiayan LI, Jianhua FAN, Ling LIN, Tingying YU, Huifang ZHANG, Li LIU. Predictive Model of Risk Factors for the Recurrence of Liver Cirrhosis with Pleural Effusion. Journal of Kunming Medical University, 2022, 43(5): 149-154. doi: 10.12259/j.issn.2095-610X.S20220524
[6]	Yanwen XU, Xin WANG, Hua JIANG, Chenchen LIANG, Li LIU, Shenghao LI, Jianpeng GAO. Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis. Journal of Kunming Medical University, 2022, 43(11): 124-129. doi: 10.12259/j.issn.2095-610X.S20221115
[7]	Yong-rui YANG, Hai-wen LI, Zhi-rong ZHAO, Lu WANG, Ting JIA, Zhi-jian DONG, Xiao-fei LI, Ni-hong LU. Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection. Journal of Kunming Medical University, 2021, 42(7): 130-136. doi: 10.12259/j.issn.2095-610X.S20210722
[8]	Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325
[9]	Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223
[10]	Jiang Ming Yuan , Huang Hua , Lu Ming Liang , Ding Wen Jing , Wang Jia Ping , Zheng Su Yun , Shi Xin . . Journal of Kunming Medical University, 2020, 41(02): 32-36.
[11]	Shi Xin Huan , Tang Rui Zhu , Liu Zi Jie , Lu Yan Zhou , Li Huan . The Changes of Hepatitis C Virus Gene Subtypes and RNA Loads in the Development of Chronic Hepatitis C Patients in Yunnan. Journal of Kunming Medical University, 2018, 39(06): 57-61.
[12]	Kang Du Fu . . Journal of Kunming Medical University,
[13]	Ji Hong . . Journal of Kunming Medical University,
[14]	Zhang Ying Ying . . Journal of Kunming Medical University,
[15]	Li Wei Hua . . Journal of Kunming Medical University,
[16]	Yang Yong Rui . . Journal of Kunming Medical University,
[17]	Wang Yun . . Journal of Kunming Medical University,
[18]	. Retrospective Analysis on Glucolipid Metabolism of 64 Patients with Liver Cirrhosis after Treatment with Recombinant Growth Hormone. Journal of Kunming Medical University,
[19]	. The Treatment of Liver Cirrhosis Complicated with Portal Hypertension by Transjugalar Intrahepatic Portosystemic Shunt (a Follow-up Study of 126 Cases). Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,